$OREX Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Orexigen Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Orexigen Therapeutics, Inc.. Get notifications about new insider transactions in Orexigen Therapeutics, Inc. for free.
Page: < prev 1 2 3 4 5 6 ... 10 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Aug 02 2013 | OREX | Orexigen Therapeut ... | Hagan Joseph P | Chief Business Offi ... | Sell | S | 7.80 | 12,000 | 93,600 | 0 | 12 K to 0 (-100.00 %) |
Aug 02 2013 | OREX | Orexigen Therapeut ... | Hagan Joseph P | Chief Business Offi ... | Buy | M | 1.66 | 12,000 | 19,920 | 12,000 | 0 to 12 K |
Jul 29 2013 | OREX | Orexigen Therapeut ... | Booth Mark D | Chief Commercial Of ... | Option Exercise | M | 1.66 | 64,767 | 107,513 | 613,924 | |
Jul 29 2013 | OREX | Orexigen Therapeut ... | Booth Mark D | Chief Commercial Of ... | Sell | S | 7.75 | 29,045 | 225,099 | 0 | 29 K to 0 (-100.00 %) |
Jul 29 2013 | OREX | Orexigen Therapeut ... | Booth Mark D | Chief Commercial Of ... | Sell | S | 7.50 | 20,000 | 150,000 | 29,045 | 49 K to 29 K (-40.78 %) |
Jul 29 2013 | OREX | Orexigen Therapeut ... | Booth Mark D | Chief Commercial Of ... | Sell | S | 7.25 | 15,722 | 113,985 | 49,045 | 64.8 K to 49 K (-24.27 %) |
Jul 29 2013 | OREX | Orexigen Therapeut ... | Booth Mark D | Chief Commercial Of ... | Buy | M | 1.66 | 64,767 | 107,513 | 64,767 | 0 to 64.8 K |
Jul 29 2013 | OREX | Orexigen Therapeut ... | Hagan Joseph P | Chief Business Offi ... | Option Exercise | M | 1.66 | 10,000 | 16,600 | 776,000 | |
Jul 29 2013 | OREX | Orexigen Therapeut ... | Hagan Joseph P | Chief Business Offi ... | Sell | S | 7.40 | 10,000 | 74,000 | 0 | 10 K to 0 (-100.00 %) |
Jul 29 2013 | OREX | Orexigen Therapeut ... | Hagan Joseph P | Chief Business Offi ... | Buy | M | 1.66 | 10,000 | 16,600 | 10,000 | 0 to 10 K |
Jul 29 2013 | OREX | Orexigen Therapeut ... | Klassen Preston | SVP, Head Global De ... | Option Exercise | M | 1.66 | 71,229 | 118,240 | 732,000 | |
Jul 29 2013 | OREX | Orexigen Therapeut ... | Klassen Preston | SVP, Head Global De ... | Sell | S | 7.16 | 71,229 | 510,000 | 0 | 71.2 K to 0 (-100.00 %) |
Jul 29 2013 | OREX | Orexigen Therapeut ... | Klassen Preston | SVP, Head Global De ... | Buy | M | 1.66 | 71,229 | 118,240 | 71,229 | 0 to 71.2 K |
Jun 07 2013 | OREX | Orexigen Therapeut ... | MAHAFFY PATRICK J | Director | Option Exercise | A | 6.09 | 35,000 | 213,150 | 35,000 | |
Jun 07 2013 | OREX | Orexigen Therapeut ... | Zoth Lota S. | Director | Option Exercise | A | 6.09 | 35,000 | 213,150 | 35,000 | |
Jun 07 2013 | OREX | Orexigen Therapeut ... | Honig Peter | Director | Option Exercise | A | 6.09 | 35,000 | 213,150 | 35,000 | |
Jun 07 2013 | OREX | Orexigen Therapeut ... | Endicott David J. | Director | Option Exercise | A | 6.09 | 35,000 | 213,150 | 35,000 | |
Jun 07 2013 | OREX | Orexigen Therapeut ... | DIXON WENDY L | Director | Option Exercise | A | 6.09 | 35,000 | 213,150 | 35,000 | |
Jun 07 2013 | OREX | Orexigen Therapeut ... | WEBER ECKARD | Director | Option Exercise | A | 6.09 | 35,000 | 213,150 | 35,000 | |
Jun 06 2013 | OREX | Orexigen Therapeut ... | BOCK LOUIS C | Director | Option Exercise | A | 6.09 | 35,000 | 213,150 | 35,000 | |
Jun 06 2013 | OREX | Orexigen Therapeut ... | DOVEY BRIAN H | Director | Option Exercise | A | 6.09 | 35,000 | 213,150 | 35,000 | |
May 30 2013 | OREX | Orexigen Therapeut ... | Klassen Preston | SVP, Head Global De ... | Option Exercise | M | 1.66 | 28,771 | 47,760 | 803,229 | |
May 30 2013 | OREX | Orexigen Therapeut ... | Klassen Preston | SVP, Head Global De ... | Sell | S | 7.21 | 28,771 | 207,358 | 0 | 28.8 K to 0 (-100.00 %) |
May 30 2013 | OREX | Orexigen Therapeut ... | Klassen Preston | SVP, Head Global De ... | Buy | M | 1.66 | 28,771 | 47,760 | 28,771 | 0 to 28.8 K |
May 30 2013 | OREX | Orexigen Therapeut ... | Hagan Joseph P | Chief Business Offi ... | Option Exercise | M | 1.66 | 28,000 | 46,480 | 786,000 | |
May 30 2013 | OREX | Orexigen Therapeut ... | Hagan Joseph P | Chief Business Offi ... | Sell | S | 7.00 | 28,000 | 196,000 | 0 | 28 K to 0 (-100.00 %) |
May 30 2013 | OREX | Orexigen Therapeut ... | Hagan Joseph P | Chief Business Offi ... | Buy | M | 1.66 | 28,000 | 46,480 | 28,000 | 0 to 28 K |
Mar 12 2013 | OREX | Orexigen Therapeut ... | Booth Mark D | Chief Commercial Of ... | Option Exercise | M | 1.66 | 27,685 | 45,957 | 678,691 | |
Mar 12 2013 | OREX | Orexigen Therapeut ... | Booth Mark D | Chief Commercial Of ... | Sell | S | 6.67 | 27,685 | 184,659 | 0 | 27.7 K to 0 (-100.00 %) |
Mar 12 2013 | OREX | Orexigen Therapeut ... | Booth Mark D | Chief Commercial Of ... | Buy | M | 1.66 | 27,685 | 45,957 | 27,685 | 0 to 27.7 K |
Feb 19 2013 | OREX | Orexigen Therapeut ... | Klassen Preston | SVP, Head Global De ... | Option Exercise | A | 5.69 | 245,000 | 1,394,050 | 245,000 | |
Feb 19 2013 | OREX | Orexigen Therapeut ... | Hagan Joseph P | Chief Business Offi ... | Option Exercise | A | 5.69 | 310,000 | 1,763,900 | 310,000 | |
Feb 19 2013 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | President and CEO | Option Exercise | A | 5.69 | 555,000 | 3,157,950 | 555,000 | |
Feb 19 2013 | OREX | Orexigen Therapeut ... | Turner Heather D | SVP, Gen. Counsel & ... | Option Exercise | A | 5.69 | 240,000 | 1,365,600 | 240,000 | |
Feb 19 2013 | OREX | Orexigen Therapeut ... | Booth Mark D | Chief Commercial Of ... | Option Exercise | A | 5.69 | 190,000 | 1,081,100 | 190,000 | |
Jan 18 2013 | OREX | Orexigen Therapeut ... | Booth Mark D | Chief Commercial Of ... | Option Exercise | M | 1.66 | 22,315 | 37,043 | 706,376 | |
Jan 18 2013 | OREX | Orexigen Therapeut ... | Booth Mark D | Chief Commercial Of ... | Sell | S | 6.68 | 100 | 668 | 0 | 100 to 0 (-100.00 %) |
Jan 18 2013 | OREX | Orexigen Therapeut ... | Booth Mark D | Chief Commercial Of ... | Sell | S | 6.67 | 22,215 | 148,174 | 100 | 22.3 K to 100 (-99.55 %) |
Jan 18 2013 | OREX | Orexigen Therapeut ... | Booth Mark D | Chief Commercial Of ... | Buy | M | 1.66 | 22,315 | 37,043 | 22,315 | 0 to 22.3 K |
Nov 30 2012 | OREX | Orexigen Therapeut ... | Endicott David J. | Director | Option Exercise | A | 4.75 | 35,000 | 166,250 | 35,000 | |
Jul 19 2012 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | President and CEO | Option Exercise | M | 1.70 | 25,762 | 43,795 | 1,774,238 | |
Jul 19 2012 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | President and CEO | Option Exercise | M | 1.66 | 124,238 | 206,235 | 1,761,562 | |
Jul 19 2012 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | President and CEO | Sell | S | 7.66 | 25,762 | 197,337 | 0 | 25.8 K to 0 (-100.00 %) |
Jul 19 2012 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | President and CEO | Buy | M | 1.70 | 25,762 | 43,795 | 25,762 | 0 to 25.8 K |
Jul 19 2012 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | President and CEO | Sell | S | 7.66 | 124,238 | 951,663 | 0 | 124.2 K to 0 (-100.00 %) |
Jul 19 2012 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | President and CEO | Buy | M | 1.66 | 124,238 | 206,235 | 124,238 | 0 to 124.2 K |
Jul 19 2012 | OREX | Orexigen Therapeut ... | Turner Heather D | SVP, Gen. Counsel & ... | Option Exercise | M | 1.66 | 82,433 | 136,839 | 1,010,963 | |
Jul 19 2012 | OREX | Orexigen Therapeut ... | Turner Heather D | SVP, Gen. Counsel & ... | Sell | S | 7.68 | 82,433 | 633,448 | 0 | 82.4 K to 0 (-100.00 %) |
Jul 19 2012 | OREX | Orexigen Therapeut ... | Turner Heather D | SVP, Gen. Counsel & ... | Buy | M | 1.66 | 82,433 | 136,839 | 82,433 | 0 to 82.4 K |
Jul 13 2012 | OREX | Orexigen Therapeut ... | Hagan Joseph P | Chief Business Offi ... | Option Exercise | M | 1.66 | 30,000 | 49,800 | 814,000 | |
Jul 13 2012 | OREX | Orexigen Therapeut ... | Hagan Joseph P | Chief Business Offi ... | Sell | S | 6.90 | 10,000 | 69,000 | 0 | 10 K to 0 (-100.00 %) |
Jul 13 2012 | OREX | Orexigen Therapeut ... | Hagan Joseph P | Chief Business Offi ... | Sell | S | 6.70 | 20,000 | 134,000 | 10,000 | 30 K to 10 K (-66.67 %) |
Jul 13 2012 | OREX | Orexigen Therapeut ... | Hagan Joseph P | Chief Business Offi ... | Buy | M | 1.66 | 30,000 | 49,800 | 30,000 | 0 to 30 K |
Jul 13 2012 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | President and CEO | Option Exercise | M | 1.66 | 147,100 | 244,186 | 1,885,800 | |
Jul 13 2012 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | President and CEO | Option Exercise | M | 1.66 | 2,900 | 4,814 | 2,032,900 | |
Jul 13 2012 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | President and CEO | Sell | S | 6.70 | 147,100 | 985,570 | 0 | 147.1 K to 0 (-100.00 %) |
Jul 13 2012 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | President and CEO | Buy | M | 1.66 | 147,100 | 244,186 | 147,100 | 0 to 147.1 K |
Jul 13 2012 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | President and CEO | Sell | S | 6.66 | 2,900 | 19,314 | 0 | 2.9 K to 0 (-100.00 %) |
Jul 13 2012 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | President and CEO | Buy | M | 1.66 | 2,900 | 4,814 | 2,900 | 0 to 2.9 K |
Jun 29 2012 | OREX | Orexigen Therapeut ... | Hagan Joseph P | Chief Business Offi ... | Option Exercise | M | 1.66 | 12,000 | 19,920 | 844,000 | |
Jun 29 2012 | OREX | Orexigen Therapeut ... | Hagan Joseph P | Chief Business Offi ... | Option Exercise | M | 1.66 | 26,000 | 43,160 | 856,000 | |
Jun 29 2012 | OREX | Orexigen Therapeut ... | Hagan Joseph P | Chief Business Offi ... | Option Exercise | M | 1.66 | 70,000 | 116,200 | 882,000 | |
Jun 29 2012 | OREX | Orexigen Therapeut ... | Hagan Joseph P | Chief Business Offi ... | Sell | S | 6.30 | 12,000 | 75,600 | 0 | 12 K to 0 (-100.00 %) |
Jun 29 2012 | OREX | Orexigen Therapeut ... | Hagan Joseph P | Chief Business Offi ... | Buy | M | 1.66 | 12,000 | 19,920 | 12,000 | 0 to 12 K |
Jun 29 2012 | OREX | Orexigen Therapeut ... | Hagan Joseph P | Chief Business Offi ... | Sell | S | 5.90 | 26,000 | 153,400 | 0 | 26 K to 0 (-100.00 %) |
Jun 29 2012 | OREX | Orexigen Therapeut ... | Hagan Joseph P | Chief Business Offi ... | Buy | M | 1.66 | 26,000 | 43,160 | 26,000 | 0 to 26 K |
Jun 29 2012 | OREX | Orexigen Therapeut ... | Hagan Joseph P | Chief Business Offi ... | Sell | S | 5.50 | 30,000 | 165,000 | 0 | 30 K to 0 (-100.00 %) |
Jun 29 2012 | OREX | Orexigen Therapeut ... | Hagan Joseph P | Chief Business Offi ... | Sell | S | 5.25 | 20,000 | 105,000 | 30,000 | 50 K to 30 K (-40.00 %) |
Jun 29 2012 | OREX | Orexigen Therapeut ... | Hagan Joseph P | Chief Business Offi ... | Sell | S | 4.90 | 20,000 | 98,000 | 50,000 | 70 K to 50 K (-28.57 %) |
Jun 29 2012 | OREX | Orexigen Therapeut ... | Hagan Joseph P | Chief Business Offi ... | Buy | M | 1.66 | 70,000 | 116,200 | 70,000 | 0 to 70 K |
Jun 29 2012 | OREX | Orexigen Therapeut ... | Booth Mark D | Chief Commercial Of ... | Option Exercise | M | 1.66 | 103,309 | 171,493 | 728,691 | |
Jun 29 2012 | OREX | Orexigen Therapeut ... | Booth Mark D | Chief Commercial Of ... | Sell | S | 5.66 | 103,309 | 584,729 | 0 | 103.3 K to 0 (-100.00 %) |
Jun 29 2012 | OREX | Orexigen Therapeut ... | Booth Mark D | Chief Commercial Of ... | Buy | M | 1.66 | 103,309 | 171,493 | 103,309 | 0 to 103.3 K |
Jun 29 2012 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | President and CEO | Option Exercise | M | 1.66 | 125,000 | 207,500 | 2,035,800 | |
Jun 29 2012 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | President and CEO | Option Exercise | M | 1.66 | 100,000 | 166,000 | 2,160,800 | |
Jun 29 2012 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | President and CEO | Sell | S | 6.08 | 125,000 | 760,000 | 0 | 125 K to 0 (-100.00 %) |
Jun 29 2012 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | President and CEO | Buy | M | 1.66 | 125,000 | 207,500 | 125,000 | 0 to 125 K |
Jun 29 2012 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | President and CEO | Sell | S | 5.66 | 100,000 | 566,000 | 0 | 100 K to 0 (-100.00 %) |
Jun 29 2012 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | President and CEO | Buy | M | 1.66 | 100,000 | 166,000 | 100,000 | 0 to 100 K |
Jun 12 2012 | OREX | Orexigen Therapeut ... | DOVEY BRIAN H | Director | Option Exercise | A | 3.12 | 35,000 | 109,200 | 35,000 | |
Jun 11 2012 | OREX | Orexigen Therapeut ... | Zoth Lota S. | Director | Option Exercise | A | 3.12 | 35,000 | 109,200 | 35,000 | |
Jun 11 2012 | OREX | Orexigen Therapeut ... | WEBER ECKARD | Director | Option Exercise | A | 3.12 | 35,000 | 109,200 | 35,000 | |
Jun 11 2012 | OREX | Orexigen Therapeut ... | BOCK LOUIS C | Director | Option Exercise | A | 3.12 | 35,000 | 109,200 | 35,000 | |
Jun 11 2012 | OREX | Orexigen Therapeut ... | MAHAFFY PATRICK J | Director | Option Exercise | A | 3.12 | 35,000 | 109,200 | 35,000 | |
Jun 11 2012 | OREX | Orexigen Therapeut ... | Honig Peter | Director | Option Exercise | A | 3.12 | 35,000 | 109,200 | 35,000 | |
Jun 11 2012 | OREX | Orexigen Therapeut ... | DIXON WENDY L | Director | Option Exercise | A | 3.12 | 35,000 | 109,200 | 35,000 | |
Apr 30 2012 | OREX | Orexigen Therapeut ... | Zoth Lota S. | Director | Option Exercise | A | 3.68 | 35,000 | 128,800 | 35,000 | |
Jan 26 2012 | OREX | Orexigen Therapeut ... | Turner Heather D | SVP, Gen. Counsel & ... | Option Exercise | A | 2.58 | 350,000 | 903,000 | 350,000 | |
Feb 28 2012 | OREX | Orexigen Therapeut ... | Booth Mark D | Chief Commercial Of ... | Option Exercise | A | 4.16 | 70,000 | 291,200 | 70,000 | |
Feb 06 2012 | OREX | Orexigen Therapeut ... | TURNER DANIEL K III | Director | Option Exercise | P | 0.00 | 28,602 | 29 | 28,602 | |
Feb 06 2012 | OREX | Orexigen Therapeut ... | TURNER DANIEL K III | Director | Option Exercise | P | 0.00 | 28,602 | 29 | 28,602 | |
Feb 06 2012 | OREX | Orexigen Therapeut ... | TURNER DANIEL K III | Director | Buy | P | 1.45 | 28,602 | 41,473 | 377,958 | 349.4 K to 378 K (+8.19 %) |
Feb 06 2012 | OREX | Orexigen Therapeut ... | TURNER DANIEL K III | Director | Buy | P | 1.45 | 28,602 | 41,473 | 177,958 | 149.4 K to 178 K (+19.15 %) |
Jan 26 2012 | OREX | Orexigen Therapeut ... | Klassen Preston | SVP, Head Global De ... | Option Exercise | A | 2.58 | 350,000 | 903,000 | 350,000 | |
Jan 26 2012 | OREX | Orexigen Therapeut ... | Booth Mark D | Chief Commercial Of ... | Option Exercise | A | 2.58 | 280,000 | 722,400 | 280,000 | |
Jan 26 2012 | OREX | Orexigen Therapeut ... | Hagan Joseph P | Chief Business Offi ... | Option Exercise | A | 2.58 | 350,000 | 903,000 | 350,000 | |
Jan 26 2012 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | President and CEO | Option Exercise | A | 2.58 | 900,000 | 2,322,000 | 900,000 | |
Dec 22 2011 | OREX | Orexigen Therapeut ... | DOMAIN PARTERS VII L P | 10% Owner | Option Exercise | P | 0.00 | 461,265 | 461 | 461,265 | |
Dec 22 2011 | OREX | Orexigen Therapeut ... | DOMAIN PARTERS VII L P | 10% Owner | Buy | P | 1.45 | 461,265 | 668,834 | 2,967,415 | 2.5 M to 3 M (+18.41 %) |
Dec 22 2011 | OREX | Orexigen Therapeut ... | DP VII ASSOCIATES LP | 10% Owner | Option Exercise | P | 0.00 | 7,882 | 8 | 7,882 | |
Dec 22 2011 | OREX | Orexigen Therapeut ... | DP VII ASSOCIATES LP | 10% Owner | Buy | P | 1.45 | 7,882 | 11,429 | 50,643 | 42.8 K to 50.6 K (+18.43 %) |
Dec 22 2011 | OREX | Orexigen Therapeut ... | SCHOEMAKER KATHLEEN K | 10% Owner | Option Exercise | P | 0.00 | 7,882 | 8 | 7,882 | |
Dec 22 2011 | OREX | Orexigen Therapeut ... | SCHOEMAKER KATHLEEN K | 10% Owner | Option Exercise | P | 0.00 | 461,265 | 461 | 461,265 | |
Dec 22 2011 | OREX | Orexigen Therapeut ... | SCHOEMAKER KATHLEEN K | 10% Owner | Buy | P | 1.45 | 7,882 | 11,429 | 50,643 | 42.8 K to 50.6 K (+18.43 %) |
Dec 22 2011 | OREX | Orexigen Therapeut ... | SCHOEMAKER KATHLEEN K | 10% Owner | Buy | P | 1.45 | 461,265 | 668,834 | 2,967,415 | 2.5 M to 3 M (+18.41 %) |
Dec 22 2011 | OREX | Orexigen Therapeut ... | BLAIR JAMES C | 10% Owner | Option Exercise | P | 0.00 | 7,882 | 8 | 7,882 | |
Dec 22 2011 | OREX | Orexigen Therapeut ... | BLAIR JAMES C | 10% Owner | Option Exercise | P | 0.00 | 461,265 | 461 | 461,265 | |
Dec 22 2011 | OREX | Orexigen Therapeut ... | BLAIR JAMES C | 10% Owner | Buy | P | 1.45 | 7,882 | 11,429 | 50,643 | 42.8 K to 50.6 K (+18.43 %) |
Dec 22 2011 | OREX | Orexigen Therapeut ... | BLAIR JAMES C | 10% Owner | Buy | P | 1.45 | 461,265 | 668,834 | 2,967,415 | 2.5 M to 3 M (+18.41 %) |
Dec 22 2011 | OREX | Orexigen Therapeut ... | VITULLO NICOLE | 10% Owner | Option Exercise | P | 0.00 | 7,882 | 8 | 7,882 | |
Dec 22 2011 | OREX | Orexigen Therapeut ... | VITULLO NICOLE | 10% Owner | Option Exercise | P | 0.00 | 461,265 | 461 | 461,265 | |
Dec 22 2011 | OREX | Orexigen Therapeut ... | VITULLO NICOLE | 10% Owner | Buy | P | 1.45 | 7,882 | 11,429 | 50,643 | 42.8 K to 50.6 K (+18.43 %) |
Dec 22 2011 | OREX | Orexigen Therapeut ... | VITULLO NICOLE | 10% Owner | Buy | P | 1.45 | 461,265 | 668,834 | 2,967,415 | 2.5 M to 3 M (+18.41 %) |
Dec 22 2011 | OREX | Orexigen Therapeut ... | TREU JESSE I | 10% Owner | Option Exercise | P | 0.00 | 7,882 | 8 | 7,882 | |
Dec 22 2011 | OREX | Orexigen Therapeut ... | TREU JESSE I | 10% Owner | Option Exercise | P | 0.00 | 461,265 | 461 | 461,265 | |
Dec 22 2011 | OREX | Orexigen Therapeut ... | TREU JESSE I | 10% Owner | Buy | P | 1.45 | 7,882 | 11,429 | 50,643 | 42.8 K to 50.6 K (+18.43 %) |
Dec 22 2011 | OREX | Orexigen Therapeut ... | TREU JESSE I | 10% Owner | Buy | P | 1.45 | 461,265 | 668,834 | 2,967,415 | 2.5 M to 3 M (+18.41 %) |
Dec 22 2011 | OREX | Orexigen Therapeut ... | Halak Brian K | 10% Owner | Option Exercise | P | 0.00 | 7,882 | 8 | 7,882 | |
Dec 22 2011 | OREX | Orexigen Therapeut ... | Halak Brian K | 10% Owner | Option Exercise | P | 0.00 | 461,265 | 461 | 461,265 | |
Dec 22 2011 | OREX | Orexigen Therapeut ... | Halak Brian K | 10% Owner | Buy | P | 1.45 | 7,882 | 11,429 | 50,643 | 42.8 K to 50.6 K (+18.43 %) |
Dec 22 2011 | OREX | Orexigen Therapeut ... | Halak Brian K | 10% Owner | Buy | P | 1.45 | 461,265 | 668,834 | 2,967,415 | 2.5 M to 3 M (+18.41 %) |
Dec 22 2011 | OREX | Orexigen Therapeut ... | DOVEY BRIAN H | Director | Option Exercise | P | 0.00 | 7,882 | 8 | 7,882 | |
Dec 22 2011 | OREX | Orexigen Therapeut ... | DOVEY BRIAN H | Director | Option Exercise | P | 0.00 | 461,265 | 461 | 461,265 | |
Dec 22 2011 | OREX | Orexigen Therapeut ... | DOVEY BRIAN H | Director | Buy | P | 1.45 | 7,882 | 11,429 | 50,643 | 42.8 K to 50.6 K (+18.43 %) |
Dec 22 2011 | OREX | Orexigen Therapeut ... | DOVEY BRIAN H | Director | Buy | P | 1.45 | 461,265 | 668,834 | 2,967,415 | 2.5 M to 3 M (+18.41 %) |
Jul 26 2011 | OREX | Orexigen Therapeut ... | Viveash Dawn | SVP/Head of Regulat ... | Option Exercise | D | 1.70 | 72,000 | 122,400 | 0 | |
Jul 26 2011 | OREX | Orexigen Therapeut ... | Viveash Dawn | SVP/Head of Regulat ... | Option Exercise | D | 2.94 | 45,000 | 132,300 | 0 | |
Jul 26 2011 | OREX | Orexigen Therapeut ... | Viveash Dawn | SVP/Head of Regulat ... | Option Exercise | D | 2.94 | 35,000 | 102,900 | 0 | |
Jul 26 2011 | OREX | Orexigen Therapeut ... | Viveash Dawn | SVP/Head of Regulat ... | Option Exercise | D | 6.74 | 30,000 | 202,200 | 0 | |
Jul 26 2011 | OREX | Orexigen Therapeut ... | Viveash Dawn | SVP/Head of Regulat ... | Option Exercise | D | 6.73 | 200,000 | 1,346,000 | 0 | |
Jul 26 2011 | OREX | Orexigen Therapeut ... | Viveash Dawn | SVP/Head of Regulat ... | Option Exercise | A | 1.66 | 382,000 | 634,120 | 382,000 | |
Jul 26 2011 | OREX | Orexigen Therapeut ... | Booth Mark D | Chief Commercial Of ... | Option Exercise | D | 2.94 | 107,000 | 314,580 | 0 | |
Jul 26 2011 | OREX | Orexigen Therapeut ... | Booth Mark D | Chief Commercial Of ... | Option Exercise | D | 2.94 | 45,000 | 132,300 | 0 | |
Jul 26 2011 | OREX | Orexigen Therapeut ... | Booth Mark D | Chief Commercial Of ... | Option Exercise | D | 6.74 | 80,000 | 539,200 | 0 | |
Jul 26 2011 | OREX | Orexigen Therapeut ... | Booth Mark D | Chief Commercial Of ... | Option Exercise | D | 8.16 | 450,000 | 3,672,000 | 0 | |
Jul 26 2011 | OREX | Orexigen Therapeut ... | Booth Mark D | Chief Commercial Of ... | Option Exercise | D | 8.16 | 150,000 | 1,224,000 | 0 | |
Jul 26 2011 | OREX | Orexigen Therapeut ... | Booth Mark D | Chief Commercial Of ... | Option Exercise | A | 1.66 | 832,000 | 1,381,120 | 832,000 | |
Jul 26 2011 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | President and CEO | Option Exercise | D | 2.94 | 258,150 | 758,961 | 0 | |
Jul 26 2011 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | President and CEO | Option Exercise | D | 2.94 | 142,650 | 419,391 | 0 | |
Jul 26 2011 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | President and CEO | Option Exercise | D | 6.74 | 360,000 | 2,426,400 | 0 | |
Jul 26 2011 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | President and CEO | Option Exercise | D | 2.79 | 1,500,000 | 4,185,000 | 0 | |
Jul 26 2011 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | President and CEO | Option Exercise | A | 1.66 | 2,260,800 | 3,752,928 | 2,260,800 | |
Jul 26 2011 | OREX | Orexigen Therapeut ... | Hagan Joseph P | Sr. VP, Corporate D ... | Option Exercise | D | 1.70 | 450,000 | 765,000 | 0 | |
Jul 26 2011 | OREX | Orexigen Therapeut ... | Hagan Joseph P | Sr. VP, Corporate D ... | Option Exercise | D | 2.94 | 107,000 | 314,580 | 0 | |
Jul 26 2011 | OREX | Orexigen Therapeut ... | Hagan Joseph P | Sr. VP, Corporate D ... | Option Exercise | D | 2.94 | 45,000 | 132,300 | 0 | |
Jul 26 2011 | OREX | Orexigen Therapeut ... | Hagan Joseph P | Sr. VP, Corporate D ... | Option Exercise | D | 6.74 | 50,000 | 337,000 | 0 | |
Jul 26 2011 | OREX | Orexigen Therapeut ... | Hagan Joseph P | Sr. VP, Corporate D ... | Option Exercise | D | 2.83 | 175,000 | 495,250 | 0 | |
Jul 26 2011 | OREX | Orexigen Therapeut ... | Hagan Joseph P | Sr. VP, Corporate D ... | Option Exercise | D | 2.83 | 125,000 | 353,750 | 0 | |
Jul 26 2011 | OREX | Orexigen Therapeut ... | Hagan Joseph P | Sr. VP, Corporate D ... | Option Exercise | A | 1.66 | 952,000 | 1,580,320 | 952,000 | |
Jul 26 2011 | OREX | Orexigen Therapeut ... | Klassen Preston | SVP, Head Global De ... | Option Exercise | D | 1.70 | 450,000 | 765,000 | 0 |